Business Monitor International


Qatar Pharmaceuticals & Healthcare Report

Published 20 March 2014

  • 97 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Qatar Pharmaceuticals & Healthcare Report

BMI View: Qatar is in top position among eight countries introducing new technology and practices in their healthcare systems, according to a study published at the World Innovation Summit for Health (WISH). Experts assessed the gap between the perceived requirements for the dissemination of information and the reality in each country: only in Qatar did the reality match the experts' ratings. Qatar's healthcare system is set for a major revamp in the next few years. The whole healthcare system is expected to develop rapidly , measured by budget and the number of facilities, and see significant upgrade s in terms of quality and services to patients. Nonetheless, there are several risks to our outlook for Qatar's pharmaceutical market. To the downside these include weaker-than-projected growth in the oil and gas sector, restricting the government's expansionary fiscal stance, delays to large-scale healthcare infrastructure projects and a widespread preference for Arab medical professional s over highly skilled expatriates. Upside risks include higher-than-expected private consumption on the back of a larger public wage bill and greater influx of foreign workers in preparation for the 2022 FIFA World Cup.

Headline Expenditure Projections

  • Pharmaceuticals: QAR1.63bn (US$449mn) in 2013 to QAR1.82bn (US$499mn) in 2014; +11.3% in local currency and 11.2% in US dollar terms. Forecast revised slightly downwards from Q114 due to macroeconomic modifications.

  • Healthcare: QAR15.30bn (US$4.20bn) in 2013 to QAR17.01bn (US$4.67bn) in 2014; +11.2% in both local currency and US dollar terms. Forecast revised slightly upwards due to macroeconomic modifications.

Risk/Reward Rating: Qatar's risks are particularly low in comparison with the rest of the MEA region, although its potential rewards are dampened by the small market size. Nevertheless, Qatar's high level of urbanisation, rapid population growth and rising prevalence of chronic lifestyle diseases creates an...

Table of Contents

BMI Industry View
7
SWOT
10
Political SWOT
12
Economic SWOT
13
Business Environment SWOT
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Qatar Pharmaceutical Sales, Historical Data and Forecasts
18
Healthcare Market Forecast
19
Table: Qatar Healthcare Expenditure Trends, Historical Data and Forecasts
20
Table: Qatar Government Healthcare Expenditure Trends, Historical Data and Forecasts
21
Table: Qatar Private Healthcare Expenditure Trends, Historical Data and Forecasts
21
Prescription Drug Market Forecast
22
Table: Qatar Prescription Drug Market Indicators, Historical Data and Forecasts
23
Patented Drug Market Forecast
23
Table: Qatar Patented Drug Market Indicators, Historical Data and Forecasts
24
Generic Drug Market Forecast
25
Table: Qatar Generic Drug Market Indicators, Historical Data and Forecasts
26
OTC Medicine Market Forecast
27
Table: Qatar Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts
28
Pharmaceutical Trade Forecast
29
Table: Qatar Pharmaceutical Trade Data And Forecasts (US$mn)
30
Table: Qatar Pharmaceutical Trade Data And Forecasts (QARmn)
31
Other Healthcare Data
31
Table: Healthcare Professionals (2009)
32
Key Risks To BMI's Forecast Scenario
32
Macroeconomic Forecasts
35
Table: Qatar - Economic Activity
42
Industry Risk Reward Ratings
43
Middle East And Africa Risk/Reward Ratings
43
Qatar Risk/Reward Ratings
51
Rewards
51
Risks
52
Market Overview
53
Industry Trends And Developments
55
Epidemiology
55
Healthcare Sector
60
Healthcare Sector Developments
61
Health Insurance
63
Healthcare IT
64
Research & Development
65
Clinical Trials
67
Regulatory Development
68
Regional Regulatory Developments
69
Intellectual Property Regime
72
Pricing And Reimbursement Regime
72
Competitive Landscape
75
Pharmaceutical Industry
75
Pharmaceutical Wholesale And Retail
76
Company Profile
77
Medicare Group
77
Ebn Sina Medical
79
Qatar Pharma
81
Novartis
83
Merck & Co
85
GlaxoSmithKline
87
Pfizer
89
Demographic Forecast
91
Table: Qatar's Population By Age Group, 1990-2020 ('000)
92
Table: Qatar's Population By Age Group, 1990-2020 (% of total)
93
Table: Qatar's Key Population Ratios, 1990-2020
94
Table: Qatar's Rural And Urban Population, 1990-2020
94
Glossary
95
Methodology
97
Pharmaceutical Expenditure Forecast Model
97
Healthcare Expenditure Forecast Model
97
Notes On Methodology
98
Risk/Reward Ratings Methodology
99
Ratings Overview
100
Table: Pharmaceutical Risk/Reward Ratings Indicators
100
Indicator Weightings
101

The Qatar Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Qatar Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Qatari pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Qatar to test other views - a key input for successful budgeting and strategic business planning in the Qatari pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Qatari pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Qatar.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc